Get started
Author

Bernard Roubert

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency
2014 · P. Ponikowski, D. J. van Veldhuisen, et al. · European Heart Journal · 1,275
PDF
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
2017 · Dirk J. van Veldhuisen, Piotr Ponikowski, et al. · Circulation · 440
PDF
Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient data Meta-Analysis
2017 · Stefan D. Anker, Bridget-Anne Kirwan, et al. · European Journal of Heart Failure · 416
PDF
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
2014 · I. C. Macdougall, A. H. Bock, et al. · Nephrology Dialysis Transplantation · 341
PDF
Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP)
2016 · Christian Breymann, Nils Milman, et al. · Journal of Perinatal Medicine · 177
PDF
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis
2023 · Piotr Ponikowski, Robert J Mentz, et al. · European Heart Journal · 145
PDF
Minimal Clinically Important Difference in Quality of Life Scores for Patients with Heart Failure and Reduced Ejection Fraction
2020 · Javed Butler, Muhammad Shahzeb Khan, et al. · European Journal of Heart Failure · 123
PDF
Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial
2017 · Claudia Trenkwalder, Juliane Winkelmann, et al. · Movement Disorders · 80
PDF
Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers
2019 · Frank Richard, Jan Jaap van Lier, et al. · American Journal of Hematology · 77
PDF
Rationale and Design of the CONFIRM-HF Study: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effects of Intravenous Ferric Carboxymaltose on Functional Capacity in Patients with Chronic Heart Failure and Iron Deficiency
2014 · Piotr Ponikowski, Dirk J. van Veldhuisen, et al. · ESC Heart Failure · 52
Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency
2022 · MUHAMMAD SHAHZEB KHAN, STEFAN D. ANKER, et al. · Journal of Cardiac Failure · 44
Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy
2014 · Michael Hedenus, Torbjörn Karlsson, et al. · Medical Oncology · 41
PDF
Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia
2020 · Yanhua Ding, Xiaoxue Zhu, et al. · Clinical Therapeutics · 21
Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency
2013 · Michael Hedenus, Torbjorn Karlsson, et al. · Blood · 6
A randomized, controlled, open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China
2023 · Jie Jin, Zhihua Ran, et al. · Frontiers of Medicine · 5
251Cardiovascular hospitalisation and death by subgroup in iron-deficient patients with heart failure treated with intravenous ferric carboxymaltose: an individual patient meta-analysis
2017 · S.D. Anker, M. Boehm, et al. · European Heart Journal · 2
Mp415effect of Intravenous Iron Therapy With Ferric Carboxymaltose on Outcomes in Iron-deficient Patients With Renal Dysfunction and Heart Failure With Reduced Ejection Fraction: an Individual Patient Data Meta-analysis of Four Randomized, Double-blind Trials
2017 · Piotr Ponikowski, Iain Macdougall, et al. · Nephrology Dialysis Transplantation · 1
Fo016hepcidin Response to Iron Therapy in Patients With Non-dialysis Ckd: an Analysis of the Find-ckd Trial
2015 · Iain C Macdougall, Andreas H Bock, et al. · Nephrology Dialysis Transplantation · 1
Pf505 First‐in‐human Single‐ and Multiple‐ascending Dose Study of the Oral Ferroportin Inhibitor Vit‐2763 in Healthy Subjects
2019 · F. Richard, J.J. van Lier, et al. · HemaSphere
252Cardiovascular and renal outcomes in iron-deficient patients with HFrEF and renal dysfunction treated with i.v. ferric carboxymaltose: An individual patient data meta-analysis
2017 · P. Ponikowski, G. Filippatos, et al. · European Heart Journal
253Effect of i.v. ferric carboxymaltose iron therapy on symptoms and functional status in iron-deficient patients with HFrEF and renal dysfunction: An individual patient data meta-analysis
2017 · P. Ponikowski, G. Filippatos, et al. · European Heart Journal
Mp417impact of Intravenous Ferric Carboxymaltose Iron Therapy on Symptoms and Functionality in Iron-deficient Patients With Heart Failure With Reduced Ejection Fraction and Renal Dysfunction: an Individualpatient Data Meta-analysis of 4 Randomized, Double-blind Trials
2017 · Piotr Ponikowski, Iain Macdougall, et al. · Nephrology Dialysis Transplantation
PDF
Works count: 22
Citation count: 3,247
H-index: 13
I10-index: 13
Year
Topic
Type